- Home
- TNON vs VYNE Comparison
TNON vs VYNE Comparison
Compare TNON & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- VYNE
- Stock Information
- Founded
- TNON 2012
- VYNE 2003
- Country
- TNON United States
- VYNE United States
- Employees
- TNON N/A
- VYNE N/A
- Industry
- TNON Medical Specialities
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- VYNE Health Care
- Exchange
- TNON Nasdaq
- VYNE Nasdaq
- Market Cap
- TNON 11.5M
- VYNE 9.6M
- IPO Year
- TNON 2022
- VYNE 2018
- Fundamental
- Price
- TNON $1.14
- VYNE $0.37
- Analyst Decision
- TNON Strong Buy
- VYNE Buy
- Analyst Count
- TNON 2
- VYNE 2
- Target Price
- TNON $5.50
- VYNE $8.00
- AVG Volume (30 Days)
- TNON 987.5K
- VYNE 1.7M
- Earning Date
- TNON 11-13-2025
- VYNE 11-06-2025
- Dividend Yield
- TNON N/A
- VYNE N/A
- EPS Growth
- TNON N/A
- VYNE N/A
- EPS
- TNON N/A
- VYNE N/A
- Revenue
- TNON $3,233,000.00
- VYNE $524,000.00
- Revenue This Year
- TNON $17.85
- VYNE N/A
- Revenue Next Year
- TNON $85.60
- VYNE N/A
- P/E Ratio
- TNON N/A
- VYNE N/A
- Revenue Growth
- TNON N/A
- VYNE 6.29
- 52 Week Low
- TNON $0.85
- VYNE $0.28
- 52 Week High
- TNON $5.85
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- TNON 43.47
- VYNE 52.17
- Support Level
- TNON $1.11
- VYNE $0.35
- Resistance Level
- TNON $1.30
- VYNE $0.38
- Average True Range (ATR)
- TNON 0.05
- VYNE 0.03
- MACD
- TNON -0.00
- VYNE 0.00
- Stochastic Oscillator
- TNON 15.79
- VYNE 60.86
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.